The global gene expression analysis market size reached USD 5.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 11.7 Billion by 2033, exhibiting a growth rate (CAGR) of 8.21% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 5.6 Billion |
Market Forecast in 2033
|
USD 11.7 Billion |
Market Growth Rate (2025-2033) | 8.21% |
Gene expression analysis (GEA) is the method of extracting data from a gene to investigate the behaviour of biological systems. It involves different processes such as gene transcription, translation, post-translational modification of protein and RNA splicing. The data obtained from this analysis is used for the production of proteins, Ribonucleic Acid (RNA) and various microbiological products. They are further utilized for the development of new drugs and improving the existing diagnostic methods. GEA is now widely considered to be essential in explaining the mechanisms that cause numerous medical ailments, owing to which it finds extensive applications in pharmacogenomics, biomarking, toxicology and diagnostics.
The increasing adoption of targeted molecular therapeutics, along with the growing demand for personalized medicines, is among the key factors driving the growth of the market. GEA has proven to be a powerful tool in molecular biology studies, which are used to understand the functioning of genes, diagnose ailments and facilitate drug development. Furthermore, the growing prevalence of chronic diseases, such as cancer, tuberculosis, and cardiovascular and genetic disorders is providing a significant boost to the market growth. Additionally, the development of personalized medicines to cure these ailments has enabled the modifications of diagnostic and treatment methods according to the individual patient requirement. Moreover, various technological advancements, such as the advent of Next Generation Sequencing (NGS), along with the development of genomic databases, higher success rates of GEA and enhanced focus on research and development (R&D) in gene therapy, are further projected to drive the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global gene expression analysis market report, along with forecasts at the global, regional and country levels from 2025-2033. Our report has categorized the market based on products & services, technology, capacity and end-user.
Breakup by Products & Services:
Breakup by Technology:
Breakup by Capacity:
Breakup by End-User:
Breakup by Region:
The competitive landscape of the industry has also been examined with some of the key players being Agilent Technologies, Inc., BGI Genomics Co., Ltd., Bio-Rad Laboratories, Inc., Eurofins GSC Lux SARL, F. Hoffmann-La Roche Ltd, GE Healthcare, Illumina, Inc., Oxford Gene Technology IP Limited, Pacific Biosciences of California Inc., PerkinElmer Inc., QIAGEN GmbH, Thermo Fisher Scientific Inc. etc.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Products & Services, Technology, Capacity, End-User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico, Argentina, Colombia, Chile, Peru ,Turkey, Saudi Arabia, Iran, United Arab Emirates |
Companies Covered | Agilent Technologies, Inc., BGI Genomics Co., Ltd., Bio-Rad Laboratories, Inc., Eurofins GSC Lux SARL, F. Hoffmann-La Roche Ltd, GE Healthcare, Illumina, Inc., Oxford Gene Technology IP Limited, Pacific Biosciences of California Inc., PerkinElmer Inc., QIAGEN GmbH and Thermo Fisher Scientific Inc., etc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global gene expression analysis market was valued at USD 5.6 Billion in 2024.
We expect the global gene expression analysis market to exhibit a CAGR of 8.21% during 2025-2033.
The rising adoption of targeted molecular therapeutics, along with the growing prevalence of genetic disorders, is primarily driving the global gene expression analysis market.
The sudden outbreak of the COVID-19 pandemic has led to the increasing utilization of gene expression analysis, as it aids in improving the functionality of the existing diagnostic methods and developing novel drugs against the coronavirus infection.
Based on the product & services, the global gene expression analysis market has been divided into consumables, instruments, and services. Among these, consumables currently exhibit a clear dominance in the market.
Based on the technology, the global gene expression analysis market can be categorized into Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), DNA microarray, sanger sequencing, and others. Currently, DNA microarray accounts for the majority of the global market share.
Based on the capacity, the global gene expression analysis market has been segregated into low-to mid-plex gene expression analysis and high-plex gene expression analysis, where high-plex gene expression analysis currently exhibits a clear dominance in the market.
Based on the end-user, the global gene expression analysis market can be bifurcated into pharmaceutical and biotech companies, academic institutes and research centers, and others. Currently, pharmaceutical and biotech companies hold the largest market share.
On a regional level, the market has been classified into North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global gene expression analysis market include Agilent Technologies, Inc., BGI Genomics Co., Ltd., Bio-Rad Laboratories, Inc., Eurofins GSC Lux SARL, F. Hoffmann-La Roche Ltd, GE Healthcare, Illumina, Inc., Oxford Gene Technology IP Limited, Pacific Biosciences of California Inc., PerkinElmer Inc., QIAGEN GmbH, Thermo Fisher Scientific Inc. etc.